MicroRNA-506 participates in pancreatic cancer pathogenesis by targeting PIM3

JUNDONG DU\(^1\)*, XI ZHENG\(^2\)*, SHOUWANG CAI\(^3\), ZIMAN ZHU\(^1\), JINGWANG TAN\(^1\), BIN HU\(^1\), ZHIQIANG HUANG\(^3\) and HUABO JIAO\(^1\)

Departments of \(^1\)Hepatobiliary Surgery and \(^2\)Division Three for Senior Officers, The First Affiliated Hospital to the General Hospital of the PLA; \(^3\)Department of Hepatobiliary Surgery, The General Hospital of the PLA, Beijing 100853, P.R. China

Received July 8, 2014; Accepted March 18, 2015

DOI: 10.3892/mmr.2015.4109

Abstract. MicroRNA (miRNA) is a type of short non-coding RNA that suppresses the expression of protein coding genes by partial complementary binding to the 3'-untranslated regions (UTRs) of mRNAs. miRNA expression alterations are involved in the initiation, progression and metastasis of human cancer and it has been suggested that miRNAs function as tumor suppressors as well as oncogenes in cancer development. PIM-3 is a member of the proto-oncogene PIM family, the aberrant expression of which exists in human pancreatic cancer tissues. There are reports indicating that overexpression of PIM3 is associated with the promotion of pancreatic cancer cell proliferation. The aim of the present study was to identify micro (mi)RNAs that regulate the expression of the oncogene PIM3 in PC. It was confirmed that the expression of PIM3 was regulated by miRNAs through an AGO2 knockout experiment. Subsequently, a dual luciferase assay system was constructed and used to screen 13 selected miRNAs that may target the PIM3 3'UTR directly. The results indicated that miR-15a/b, miR-16, miR-33a/b, miR-124, miR-195 and miR-506 repressed the luciferase activity by targeting the PIM3 3'UTR. However, only the expression of miR-506 was negatively correlated with PIM3 expression in PC tissues (r=-0.38, P=0.017). Furthermore, a biological functional study indicated that miR-506 functioned as a tumor suppressor by repressing PC cell proliferation, which was partially reversed by PIM3 overexpression. To the best of our knowledge, the present study was the first to reveal the tumor suppressor function of miR-506 in PC, which has the potential to be employed in the diagnosis and treatment of PC.

Introduction

Pancreatic cancer (PC) is an aggressive malignancy with one of the highest mortality rates amongst cancers worldwide. It is the sixth leading cause of mortality from malignant disease in China and the fourth leading cause of cancer-associated mortality in the USA (1-3). Rapid tumor progression, late diagnosis, early and aggressive metastasis and high resistance to conventional chemotherapy lead to exceptionally poor prognosis with an overall five-year survival rate of <5% (4). Therefore, novel markers for early diagnosis and novel therapeutic targets for PC require to be identified. Although the etiology of PC is also attributed to numerous environmental factors, the accumulation of genetic and epigenetic changes remains the fundamental mechanism of tumorigenesis (5-7).

MicroRNA (miRNA/miR) is a type of short non-coding RNA that suppresses the expression of protein-coding genes by partial complementary binding, particularly to the 3'-untranslated regions (3'UTRs) of mRNAs. miRNA expression alterations are involved in the process of pathogenesis and drug resistance (10,11). Accumulating studies have shown that disturbed expression of miRNAs is involved in the process of pathogenesis and drug resistance (10,11).

PIM3 was initially identified as a novel gene that is induced by membrane depolarization or forskolin in the rat pheochromocytoma cell line PC12 and was designated as a kinase induced by depolarization (KID)-1 (12). However, KID-1 was renamed PIM3 because it showed high sequence similarity with the proto-oncogenic provirus integrating site Moloney murine leukemia virus (PIM) family of proteins (13). Recently, PIM3 was found to be aberrantly expressed in pancreatic ductal adenocarcinoma (PDAC) cells and to phosphorylate the pro-apoptotic protein B-cell lymphoma 2-associated death promoter (14). In addition, PIM3 was shown to be regulated by transcription factors such as ETS-1 and serve as a positive

\*Contributed equally

Key words: microRNA, PIM3, pancreatic cancer, cell proliferation

Correspondence to: Dr Zhiqiang Huang, Department of Hepatobiliary Surgery, The General Hospital of the PLA, 28 Fuxing Road, Beijing 100853, P.R. China
E-mail: zhiqianghuangcn@163.com

Dr Huabo Jiao, Department of Hepatobiliary Surgery, The First Affiliated Hospital to the General Hospital of the PLA, 51 Fucheng Road, Beijing 100853, P.R. China
E-mail: huaboj@163.com

\*Contributed equally

Key words: microRNA, PIM3, pancreatic cancer, cell proliferation
regulator of signal transducer and activator of transcription 3 signaling in PC cells (15,16).

The present study aimed to investigate the post-transcriptional regulation of the expression of PIM3 in PC, focusing on miRNAs directly targeting PIM3.

Materials and methods

**Cell culture.** PANC-1, MIAPaCa-2 and HEK293T cells (China Infrastructure of Cell Line Resources, Beijing, China) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (HyClone, Logan, UT, USA), 100 IU/ml penicillin and 10 mg/ml streptomycin (HyClone). All cells were maintained at 37˚C under an atmosphere of 5% CO₂.

**Tissue samples.** PC and matched adjacent normal tissues from 38 patients were obtained post-operatively from March to September in 2012 from the Department of Hepatobiliary Surgery, The First Affiliated Hospital to the General Hospital of the PLA (Beijing, China). The patients provided signed, informed consent for their tissues to be used for scientific research. Ethical approval for the study was obtained from the First Affiliated Hospital to the General Hospital of the PLA. Diagnoses were based on pathological and/or cytological evidence. Histological features of the specimens were evaluated by two senior pathologists according to classification criteria from the World Health Organization (17). Tissues were obtained from patients prior to chemotherapy or radiation therapy. Specimens were immediately frozen and stored at -80°C prior to western blot and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analyses.

**Western blot analysis.** Protein extracts were boiled in SDS/β-mercaptoethanol sample buffer (Sigma-Aldrich, St. Louis, MO, USA), and 30 μg of each sample was loaded onto a lane of a 12% polyacrylamide gel (Sigma-Aldrich). The proteins were separated by electrophoresis, and the proteins in the gels were blotted onto polyvinylidene difluoride membranes (GE Healthcare, Little Chalfont, UK) by electrophoretic transfer. The membrane was incubated with rabbit anti-PIM3 monoclonal antibody (1:1,000; ab75776; Abcam, Cambridge, MA, USA), mouse anti-β-actin monoclonal antibody (1:1,000; sc-58673; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or rabbit anti-AGO2 monoclonal antibody (1:1,000; ab186733; Abcam) for 1 h at 37°C. The specific protein-antibody complex was detected by horseradish peroxidase-conjugated goat anti-rabbit (sc-2004) or rabbit anti-mouse (sc-358920; Abcam) (1:1,000; sc-58673; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or rabbit anti-AGO2 monoclonal antibody (1:1,000; ab186733; Abcam) for 1 h at 37°C. The specific protein-antibody complex was detected by horseradish peroxidase-conjugated goat anti-rabbit (sc-2004) or rabbit anti-mouse (sc-358920; Abcam) (1:1,000; sc-58673; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or rabbit anti-AGO2 monoclonal antibody (1:1,000; ab186733; Abcam) for 1 h at 37°C. The specific protein-antibody complex was detected by horseradish peroxidase-conjugated goat anti-rabbit (sc-2004) or rabbit anti-mouse (sc-358920; Abcam) (1:1,000; sc-58673; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or rabbit anti-AGO2 monoclonal antibody (1:1,000; ab186733; Abcam) for 1 h at 37°C.

**RT-qPCR analysis.** RT-qPCR analysis was used to determine the relative expression levels of 13 selected miRNAs. Total RNA was extracted from tissues, using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The expression levels of candidate miRNAs were detected by TaqMan miRNA RT-Real Time PCR (Applied Biosystems Life Technologies, Foster City, CA, USA). Single-stranded cDNA was synthesized by using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems Life Technologies, Waltham, MA, USA) and then amplified by using TaqMan Universal PCR Master Mix (Applied Biosystems Life Technologies) together with miRNA-specific TaqMan Minor Groove Binder probes (Applied Biosystems Life Technologies). U6 small nuclear RNA was used for normalization. The experiments were processed using an ABI 7300 PCR Thermal Cycler (Applied Biosystems Life Technologies). The protocol for qPCR was a classic two step PCR: 95°C for 10 min; 95°C for 15 sec followed by 60°C for 1 min for 35 cycles. Each sample in each group was measured in triplicate and the experiment was repeated at least three times. The relative expression was calculated using the ΔΔCt method. The products were separated by 2% agarose (Sigma-Aldrich) to confirm the specificity of the PCR reaction.

**3'UTR luciferase reporter assays.** To generate the 3'UTR luciferase reporter, the full-length 3'UTR from PIM3 was cloned into the downstream region of the firefly luciferase gene in the pGL3-control vector (Promega, Madison, WI, USA). The primer sequences for PIM 3'UTR cloning were as follows: PIM3, forward CTCGAGGGAGCTGCACCTG ACTGGGA and reverse TCTAGATATGTACAAAAACA.
TTTTAATTGAAATACC. The primers were synthesized by BGI-GBI Biotech Co., Ltd. (Beijing, China). miRNA mimics and inhibitor were synthesized by GenePharma Co., Ltd (Shanghai, China). The sequence for the double strand miR-506 mimic was 5'-UAA GGC ACC CUU CUG AGU AGA-3', for the single strand miR-506 inhibitor was 5'-TCT ACT CAG AAG GGT GCC TTA-3', for the miR-506 control was 5'-UUC UCC GAA CGU GUC ACU UTT-3' and for the miR-506 inhibitor control was 5'-CAG UAC UUU GUA GUA CAA-3'.

The pRL-TK vector (Promega) containing Renilla luciferase was co-transfected for data normalization. For luciferase reporter assays, HEK293T cells were seeded in 48-well plates. Luciferase reporter vectors were co-transfected with one of the miRNA mimics or using Lipofectamine 2000 (Invitrogen Life Technologies). Two days post-transfection, cells were harvested and assayed using the Dual-Luciferase Assay system (Promega). Each treatment was performed in triplicate in three independent experiments. The results were expressed as relative luciferase activity (firefly luciferase light units/Renilla luciferase light units). To identify the binding site of miR-506, a plasmid with three nucleotide mutations in the predicted miR-506 binding site was used.

AGO2 knockdown. Pancreatic cancer cell lines PANC-1 and MIAPaca-2 were transfected with AGO2 siRNA and the corresponding control using Lipofectamine 2000 (Invitrogen Life Technologies). A total of 48 h subsequent to transfection, the cells were lysed by RIPA Lysis and Extraction Buffer (Pierce Biotechnology) and the expression of AGO2 and IPM3 was detected by western blot analysis. β-actin was used as loading control.

Cell proliferation assay. PANC-1 and MIAPaca-2 cells were seeded in 96-well plates at a low density (5x10^3) in DMEM culture and allowed to attach overnight. The cells were then transfected with miR-506 mimic or inhibitor, with a scrambled-sequence single strand or double strand short hairpin RNA as the control. MTT (20 µl; 5 mg/ml; Sigma-Aldrich) was added into each well 48 h after transfection, and the cells were incubated for a further 4 h. Following addition of dimethyl sulfoxide (Sigma-Aldrich), the absorbance was measured at 570 nm using a 96-well plate reader.

Statistical analysis. Data were analyzed by using SPSS Statistical Package version 17 (SPSS, Inc., Chicago, IL, USA). Results were analyzed using Student's t-test. P<0.05 was considered to indicate a statistically significant difference between values. The results of the luciferase and MTT assays were displayed as the mean ± standard deviation. The results of miRNA expression in the clinical samples were exhibited using box-and-whisker plots, where the whisks represented the range of the data.
Results

PIM3 expression in PC cells is regulated by miRNAs. To explore whether the expression of PIM3 is regulated by miRNAs, argonaute RNA-induced silencing complex (RISC) catalytic component 2 (AGO2), the key component of the RISC complex was knocked down in PANC-1 and MIAPaca-2 cells. It was observed that the inactivation of the RISC complex caused a marked upregulation of PIM3 expression (Fig. 1A). The result indicated that miRNAs participate in the inverse control system of PIM3 expression.

Five out of thirteen selected miRNAs target PIM3 directly. To identify which miRNAs repress PIM3 expression directly, a reporter vector containing the full-length PIM3 3’UTR downstream of the firefly luciferase coding region was constructed (Fig. 1B). miRNAs that may target the PIM3 3’UTR were predicted using the online bioinformatics tool TargetScan (http://www.targetscan.org), and thirteen miRNAs were selected: miR-15a, miR-15b, miR-16, miR-33a, miR-33b, miR-124, miR-195, miR-203, miR-322, miR-424, miR-497 and miR-506. After screening by using the dual luciferase system, we seven miRNAs (miR-15a, miR-15b, miR-33a, miR-33b, miR-124, miR-195 and miR-506) were identified to repress luciferase activity by significantly targeting the PIM3 3’UTR (Fig. 1C).

Association between miRNAs and PIM3 expression. To explore the association between PIM3 and miRNAs in PC samples, PIM3 expression was detected by western blot analysis and the expression of seven selected miRNAs was detected by RT-qPCR (Fig. 2). miR-195 and miR-506 were significantly downregulated in tumor tissue samples compared with normal adjacent tissues (P<0.05 and P<0.01, respectively). An example of PIM3 expression in PC and paired normal control tissues is shown in Fig. 3A. The results indicated that ~74% (29/38) of PC tissues displayed upregulated PIM3 expression and ~71% (27/38) or 63% (23/38) had downregulated miR-506 or miR-195 expression, respectively (Fig. 3B).

To reveal the correlation between downregulated miRNAs (miR-195 and miR-506) and the PIM3 in PC tissues, PIM3 expression was assessed using western blot analysis. An inverse correlation was identified between the expression levels of miR-506 and PIM3 in 38 clinical samples of PC. Low levels of miR-506 were associated with high PIM3 expression (Pearson correlation, r= -0.38; P=0.017; Fig. 3B).
miR-506 represses PIM3 expression by directly targeting its 3'UTR. To further confirm whether PIM3 is the target gene of miR-506, the dual luciferase assay system was utilized again. HEK293T cells were co-transfected with pGL3-PIM3 and miR-506 mimic or inhibitor. As shown in Fig. 4A, compared with the miRNA control, the miR-506 mimic significantly suppressed the luciferase activity by 45.2% (P<0.01). Furthermore, the luciferase activity was significantly upregulated (by 35.7%) by the miR-506 inhibitor compared with that in the miR-inhibitor control (P<0.05). These changes of firefly luciferase translation indicated that miR-506 targets the 3'UTR of PIM3.

A seed sequence mutation clone was also used to further confirm the binding site for miR-506 (Fig. 4B). A vector containing a putative miR-506 binding region in the 3'UTR of PIM3 with three mutant nucleotides (designated as pGL3-PIM3-Mu) was constructed. The bar graph in Fig. 4C shows that the enzyme activity was not significantly reduced in cells transfected with miR-control compared with that in cells transfected with miR-506 mimic (P>0.05). This result indicated that miR-506 may suppress PIM3 expression through binding to the seed sequence at the 3'UTR of PIM3.

To further examine whether endogenous PIM3 expression is suppressed by miR-506, PANC-1 cells were transfected with miR-506 mimic or inhibitor. PIM3 protein levels were detected by western blot analysis 48 h post-transfection. Compared with the corresponding control, the levels of PIM3 protein were significantly suppressed by miR-506 mimic and upregulated by miR-506 inhibitor in PANC-1 cells (Fig. 4D). These results indicated that miR-506 repressed endogenous PIM3 expression in PC cells by directly targeting the PIM3 3'UTR, and PIM3 is a target gene of miR-506.

miR-506 suppresses PC cell proliferation. To further test whether miR-506 may execute tumor-suppressive functions by targeting PIM3, the effect of miR-506-mediated cell proliferation was assessed using an MTT assay on PANC-1 (Fig. 5A) and MIAPaca-2 cells (Fig. 5B). The cell proliferation ability was significantly reduced by the miR-506 mimic (by 52.8%) in PANC-1 cells and by 33.1% in MIAPaca-2 cells. Furthermore, cell proliferation was significantly upregulated by the miR-506 inhibitor (by 43.2%) in PANC-1 cells and by 32.3% in MIAPaca-2 cells. To further confirm whether miR-506
represses cell proliferation by targeting PIM3, a PIM3 expression vector was co-transfected with miR-506 mimic into PANCl and MIA PaCa-2 cells. As shown in Fig. 5A and B (right), the PIM3 expression vector partially reversed the repressed cell proliferation caused by miR-506 overexpression, indicating that miR-506 suppresses PC cell proliferation partially through targeting PIM3.

Discussion

PIM3 is a member of the proto-oncogenic PIM family that encodes serine/threonine kinases, and is aberrantly expressed in human PC. Studies have indicated that overexpression of PIM3 is associated with enhanced PC cell proliferation (18). In the present study, it was confirmed that the expression of PIM3 is regulated by miRNAs through an AGO2 knockout experiment. Subsequently, a dual luciferase assay system was constructed and used for screening 13 selected miRNAs that may target the PIM3 3'UTR directly according to a TargetScan analysis. The results indicated that miR-15a/b, miR-16, miR-33a/b, miR-195 and miR-506 repressed luciferase activity by targeting the PIM3 3'UTR. However, only the expression of miR-506 was negatively correlated with PIM3 expression in the PC tissues (r=−0.38, P=0.017). Furthermore, a mechanistic study indicated that miR-506 acted as a tumor suppressor by repressing PC cell proliferation and its anti-proliferative function can be partially reversed by PIM3 overexpression.

Biological functions of miR-506, particularly in cancer, have been studied; however, the roles of miR-506 in carcinogenesis are yet to be elucidated (19,20). In breast, cervical and ovarian cancer, miR-506 is confirmed to be a tumor suppressor through targeting Ki-67, Gli3, CDK4 and CDK6 (20-22). Furthermore, downregulation of miR-506 in cervical cancer was identified to be associated with the cancer pathogenesis (20). However, miR-506 overexpression was also reported in lung cancer and melanoma; however, they appear to have opposite functions. Yin et al (23) reported that miRNA-506 was upregulated in lung cancer patients and its overexpression selectively killed lung cancer cells through inhibiting nuclear factor-κB p65 to evoke the generation of reactive oxygen species and p53 activation. By contrast, Streicher et al (24) reported that the miRNA-506-514 cluster was overexpressed in almost all melanoma samples that were assessed and had a positive role in initiating melanocyte transformation and promoting melanoma growth. The present study was the first, to the best of our knowledge, to report that miR-506 was downregulated in PC tissues, which may be applicable for clinical diagnosis. However, since one miRNA may have tens or hundreds of target genes and its function may be tissue-specific, further studies are required to fully unveil the biological functions of miR-506.

References